Get the Stockscreener App
1.18
0.00%
0.00
After Hours:
1.14
-0.04
-3.39%
Ovid Therapeutics Inc stock is traded at $1.18, with a volume of 61,263.
It is up +0.00% in the last 24 hours and up +4.42% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
See More
Previous Close:
$1.18
Open:
$1.18
24h Volume:
61,263
Relative Volume:
0.18
Market Cap:
$83.75M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-1.6857
EPS:
-0.7
Net Cash Flow:
$-45.92M
1W Performance:
+6.31%
1M Performance:
+4.42%
6M Performance:
-61.31%
1Y Performance:
-69.27%
1-Day Range:
$1.15
$1.19
1-Week Range:
$1.07
$1.19
52-Week Range:
$0.68
$4.10
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely? - Yahoo Finance
HC Wainwright Reaffirms "Buy" Rating for Ovid Therapeutics (NASDAQ:OVID) - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Ovid Therapeutics (NASDAQ:OVID) - Defense World
Driehaus Capital Management LLC Invests $1.08 Million in Ovid Therapeutics Inc. (NASDAQ:OVID) - MarketBeat
Ovid stock gets boost from promising OV329 toxicity profileB.Riley - Investing.com
Ovid reports promising safety profile for epilepsy drug OV329 - Investing.com
Ovid Therapeutics Presents Pre-Clinical Study Results - GlobeNewswire
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with Vigabatrin - StockTitan
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Lombard Odier Asset Management USA Corp Has $236,000 Stock Position in V2X, Inc. (NYSE:VVX) - Defense World
Murchinson Ltd. Trims Stock Holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) - MarketBeat
Market Resilience: Vor Biopharma Inc (VOR) Finishes Weak at 0.83, Down -7.78 - The Dwinnex
Lombard Odier Asset Management Europe Ltd Makes New Investment in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World
The Attractiveness of Investing In OmniAb Inc (OABI) is Growing - Knox Daily
Oxford Biomedica Sees Robust Growth in 2024 - TipRanks
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 6.3% - Defense World
Victory Capital Management Inc. Has $991,000 Holdings in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World
DCF Advisers LLC Boosts Stock Position in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Ovid Therapeutics (NASDAQ:OVID) Shares Cross Below Fifty Day Moving Average of $1.06 - MarketBeat
Q3 2025 EPS Estimates for ModivCare Inc. (NASDAQ:MODV) Reduced by Analyst - MarketBeat
Victory Capital Management Inc. Increases Position in OneMain Holdings, Inc. (NYSE:OMF) - Defense World
Ovid Therapeutics (NASDAQ:OVID) Stock Passes Below 50 Day Moving Average of $1.06 - Defense World
Checking in on OmniAb Inc (OABI) after recent insiders movement - Knox Daily
Is OmniAb Inc (OABI) positioned for future growth? - SETE News
Federated Hermes Inc. Purchases 5,323 Shares of Ovintiv Inc. (NYSE:OVV) - Defense World
Box announces pricing of $400M debt offering via issuance of convertible senior notes due 2029 - MSN
Oxford Biomedica Emerges as OXB with Global Vision - TipRanks
Recent Insider Activity Could Benefit Olo Inc (OLO) - Knox Daily
ModivCare (NASDAQ:MODV) PT Lowered to $19.00 - MarketBeat
Gaining Ground: Outset Medical Inc (OM) Closes Lower at 0.52, Down -1.34 - The Dwinnex
Levi & Korsinsky Notifies Outset Medical, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – OM - ForexTV.com
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech - Pharmaceutical Technology
FDA approves new multiple sclerosis treatment OCREVUS ZUNOVO By Investing.com - Investing.com Australia
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis - Citizentribune
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis - PR Newswire
Ovid Therapeutics names new President and COO - Investing.com India
Moderna Pulls Back on R&D and Delays Timeline for Profitability. The Stock Tumbles. - MSN
Moderna slashes research spending, trims pipeline as it looks to regain footing - MSN
Ovid Therapeutics appoints new president and COO - Investing.com
Meg Alexander takes on expanded role at Ovid Therapeutics - The Pharma Letter
Ovid Therapeutics names new President and COO - Investing.com
Ovid Therapeutics Elevates Meg Alexander to President and COO - TipRanks
Ovid Therapeutics appoints new president and COO - Investing.com India
Meg Alexander Appointed COO of Ovid Therapeutics - citybiz
Monitoring Ovid Therapeutics Inc (OVID) after recent insider movements - Knox Daily
Ovid Therapeutics appoints new president and COO By Investing.com - Investing.com UK
Meg Alexander Takes on Expanded Role as President and COO - GlobeNewswire
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth - StockTitan
Fragile X Syndrome Market 2032, Insights by Delveinsight | - openPR
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Ovid Therapeutics Inc. (NASDAQ:OVID) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):